Sequential, randomized trial of a low-fat, high-fiber diet and soy supplementation: Effects on circulating IGF-I and its binding proteins in premenopausal women

✍ Scribed by Peter H. Gann; Ralph Kazer; Robert Chatterton; Susan Gapstur; Kim Thedford; Irene Helenowski; Sue Giovanazzi; Linda Van Horn

• Publisher: John Wiley and Sons
• Year: 2005
• Tongue: French
• Weight: 164 KB
• Volume: 116
• Category: Article
• ISSN: 0020-7136
• DOI: 10.1002/ijc.21042

✦ Synopsis

Abstract

Despite evidence supporting the involvement of the IGF system in the development of breast and other cancers, the major determinants of interindividual variability in circulatory IGF‐I levels are not well understood. Previous research has pointed to important genetic influences as well as dietary effects through marked calorie or protein restriction. We conducted a randomized trial to determine the effects of 2 dietary patterns on serum IGF‐1, IGFBP1 and IGFBP3 in free‐living premenopausal women: phase 1, an isocaloric low‐fat, high‐fiber (LFHF) vs. usual diet, and phase 2, a soy supplement either with or without isoflavones (soy+IF vs. soy–IF). Participants completed 12 menstrual cycles on phase 1 and then were randomly assigned to a soy supplement for 3 cycles while maintaining the phase 1 diet. Before and after each phase, 154 women provided serum. We found no difference in the change in IGF‐I, BP1 or BP3 in the LFHF group compared to the usual diet group. In phase 2, there were no differences in any IGF protein between the soy+IF and the soy–IF groups or any evidence of interaction between isoflavone exposure and the background diet. However, there was a small but statistically significant decrease (2.3%) in BP3 and an increase in the IGF‐I:BP3 molar ratio among all 153 subjects following either soy supplement. These changes were correlated with changes in intake of calcium, total vegetable protein and soy. The results are compatible with previous data suggesting that increases in dietary calcium, protein and soy, in particular, could increase circulating levels of bioavailable IGF‐I. © 2005 Wiley‐Liss, Inc.